Ravi Shah, MD
Ophthalmology · Homewood, ILNPI 1295186872
Payments from drug & device makers
Across 135 payments — averaging $35.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$655
- Bausch & Lomb Americas Inc.$588
- Rxsight Inc$406
- Glaukos Corporation$365
- Dompe US, Inc.$316
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 25 | $1,154 |
| AbbVie(2 entities) | 33 | $655 |
| Bausch & Lomb Americas Inc. | 15 | $588 |
| Rxsight Inc | 5 | $406 |
| Glaukos Corporation | 9 | $365 |
| Dompe US, Inc. | 9 | $316 |
| Tarsus Pharmaceuticals, Inc. | 3 | $216 |
| Carl Zeiss Meditec USA, Inc. | 1 | $190 |
| Oyster Point Pharma, Inc. | 8 | $188 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Harrow Eye, LLC | 5 | $124 |
| NEW World Medical,inc. | 6 | $99 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $88 |
| Abbott | 2 | $71 |
| Biotissue Holdings Inc. | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof$512
- MIEBO$354
- RXSIGHT CONTACT LENS$276
- RXSIGHT INJECTOR CARTRIDGE$276
- RXSIGHT INJECTOR HANDPIECE$276
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$276
- XIIDRA$229
- EQ Workplace$190
- LIGHT ADJUSTABLE LENS (LAL)$163
- XDEMVY$159
- Photrexa Viscous and Photrexa$137
- DURYSTA$133
- EYLEA$125
- LUMIGAN$125
- COMBIGAN$125
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
- TYRVAYA$103
How this compares
$4,807 in reported general payments places this provider in the 75th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 58 | $2,478,144 |
| LumiganBimatoprost | 231 | $112,288 |
| XiidraLifitegrast | 77 | $102,564 |
| TyrvayaVarenicline Tartrate | 55 | $71,529 |
| VyzultaLatanoprostene Bunod | 146 | $64,584 |
| RestasisCyclosporine | 55 | $63,050 |
| MieboPerfluorohexyloctane/Pf | 51 | $46,817 |
| Lotemax SmLoteprednol Etabonate | 143 | $35,871 |
| VevyeCyclosporine | 30 | $23,702 |
| CombiganBrimonidine Tartrate/Timolol | 51 | $18,659 |
| RhopressaNetarsudil Mesylate | 18 | $11,577 |
| Prednisolone Acetate | 408 | $10,799 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $9,958 |
| Latanoprost | 829 | $9,854 |
| Travoprost | 39 | $9,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $316 | $2,478,14458 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $588 | $213,965274 claims |
| AbbVieLumigan, Restasis, Combigan | $655 | $193,997337 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $188 | $71,52955 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Lotemax | $24 | $40,551155 claims |
| Harrow Eye, LLCVevye | $124 | $23,70230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Homewood
- David LubeckHomewood$709K
- Richard QuinonesHomewood$178K
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
- Kathleen MornoNorth Riverside$1.2M
- Amani FawziChicago$864K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.